Antiviral drugs

There is no antiviral drug globally accepted for treatment, but many drugs are under investigations. About 21 trials of antivirals are under development (5th May 2020).
Antiviral drugs are difficult to find, because of the cell-parasitic nature of viruses. It has been long to get efficient drugs against HIV or Hepatitis C. COVID-19 vaccine may arrive before we get efficient antivirals.

External resource

ANTIVIRAL DRUGS This table displays the main drugs under investigation

Class Compound Ref Status for Covid-19 Notes
Spike maturation inhibitor Camostat Under investigation TMPRSS2 inhibitor that may prevent Spike cleavage and activation. Spike could still be activated by furin
Fusion inhibitor Hydroxychloroquine No-benefit in clinical trials
Non-specific anti-malaria drug. May prevent virus entry by modifying endosomal pH.
Umifenovir/Arbidol Non-effective in clinical trials Anti influenza drug
Protease inhibitor Ritonavir , Lopinavir No-benefit in clinical trials? Molecules targeting HIV protease which is a ASP protease, but SARS-Cov proteases are THIOL proteases.
Darunavir No evidence of SARS-CoV-2 inactivation
Viral polymerase inhibitor Remdesivir Weakly effective in clinical trials Molecule under investigation against MERS and SARS coronaviruses.
Favipiravir No evidence of SARS-CoV-2 inactivation, under investigation Drug developed against influenza, redirected against ebola and now SARS-CoV-2